Epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs), including gefitinib and erlotinib, are reversible competitive inhibitors of the tyrosine kinase domain of EGFR, binding to its adenosine-5'-triphosphate (ATP)-binding site1. The presence of somatic activating mutations in the EGFR gene, an increased gene copy number, and specific clinical and morphological tumour characteristics correlate with the high efficacy of these inhibitors, leading to significant tumour regression and improved clinical outcomes in patients with non-small-cell lung cancer (NSCLC)2